GLP-1

Base Information

• Chemical Name: GLP-1
• CAS No.: 87805-34-3
• Molecular Formula: C186H275 N51 O59
• Molecular Weight: 4169.53
• Hs Code.: 3504009000
• ChEMBL ID: CHEMBL2158410
• DSSTox Substance ID: DTXSID10236651
• Mol file: 87805-34-3.mol

Synonyms:164: PN:WO0069900 SEQID: 343 unclaimed protein; 167: PN: WO2004005342 PAGE: 46 claimedprotein; 1: PN: WO0066142 SEQID: 1 unclaimed protein; 1: PN: WO0069911 SEQID: 1claimed protein; 1: PN: WO2009033711 PAGE: 1 claimed protein; 20: PN:WO2007028394 SEQID: 1 claimed protein; 276: PN: US20090175821 SEQID: 343claimed protein; 29: PN: WO2009099763 SEQID: 667 claimed protein; 2: PN:DE102004043153 PAGE: 13/17 claimed protein; 7: PN: WO2004005342 PAGE: 46claimed protein; 9: PN: US6284725 SEQID: 1 unclaimed protein; 9: PN: WO0066138PAGE: 11 unclaimed protein; Glucagon-like peptide I (ox); Glucagon-like peptideI (rat); Glycine, L-histidyl-L-a-aspartyl-L-a-glutamyl-L-phenylalanyl-L-a-glutamyl-L-arginyl-L-histidyl-L-alanyl-L-a-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-a-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-a-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-;Human glucagon-like peptide 1; Rat GLP-I(1-37)

Chemical Property of GLP-1

Chemical Property:

• Appearance/Colour: White lyophilized powder
• Storage Temp.: −20°C
• XLogP3: -17.1
• Hydrogen Bond Donor Count: 63
• Hydrogen Bond Acceptor Count: 66
• Rotatable Bond Count: 140
• Exact Mass: 4168.0119754
• Heavy Atom Count: 296
• Complexity: 10100

Purity/Quality:

98%,99%, ^*data from raw suppliers

Glucagon-Like Peptide 1, Human ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC8=CN=CN8)N
• Isomeric SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC8=CN=CN8)N
• Description: GLP-1 stimulates pancreatic β cells to secrete insulin as an incretin hormone. GLP-1 also has additional actions, including suppression of glucagon secretion, inhibition of gastric motility, and promotion of satiety.
• Uses: Glucagon-Like Peptide I (GLP1) has been used as an antigen in excess amounts for the incubation of primary antibodies, post-immunocytochemistry with positive results of paraffin-embedded pancreatic tissues of Rana temporaria.
• Clinical Use: GLP-1 enhances glucose-stimulated insulin release. GLP-1 agonists are resistant to degradation by DPP-4; thus these agonists are used clinically for the treatment of diabetes. DPP-4 inhibitors are also acceptable for use in diabetes patients because GLP-1 is rapidly deactivated by DPP-4.